

Certain heterozygous variants in the kinase domain of the serine/threonine kinase NEK8 can cause an autosomal dominant form of polycystic kidney disease.

Laura R. Claus, Chuan Chen, Jennifer Stallworth, Joshua L. Turner, Gisela Slaats, Alexandra L. Hawks, Holly Mabillard, Sarah R. Senum, Sujata Srikanth, Heather Flanagan-Steet, Raymond J. Louie, Josh Silver, Jordan Lerner-Ellis, Chantal Morel, Chloe Mighton, Frank Sleutels, Marjon van Slegtenhorst, Tjakko van Ham, Alice S. Brooks, Eiske M. Dorresteyn, Tahsin Stefan Barakat, Karin Dahan, Nathalie Demoulin, Eric Jean Goffin, Eric Olinger, Genomics England Research Consortium, Martin Larsen, Jens Michael Hertz, Marc R. Lilien, Lena Obeidová, Tomas Seeman, Hillary K. Stone, Larissa Kerecuk, Mihai Gurgu, Fjodor A. Yousef Yengej, Carola ME. Ammerlaan, Maarten B. Rookmaaker, Christian Hanna, R. Curtis Rogers, Karen Duran, Edith Peters, John A. Sayer, Gijs van Haaften, Peter C. Harris, Kun Ling, Jennifer M. Mason, Albertien M. van Eerde, Richard Steet

PII: S0085-2538(23)00559-8

DOI: <https://doi.org/10.1016/j.kint.2023.07.021>

Reference: KINT 3553

To appear in: *Kidney International*

Received Date: 29 July 2022

Revised Date: 22 July 2023

Accepted Date: 28 July 2023


Please cite this article as: Claus LR, Chen C, Stallworth J, Turner JL, Slaats G, Hawks AL, Mabillard H, Senum SR, Srikanth S, Flanagan-Steet H, Louie RJ, Silver J, Lerner-Ellis J, Morel C, Mighton C, Sleutels F, van Slegtenhorst M, van Ham T, Brooks AS, Dorresteyn EM, Barakat TS, Dahan K, Demoulin N, Goffin EJ, Olinger E, Genomics England Research Consortium, Larsen M, Hertz JM, Lilien MR, Obeidová L, Seeman T, Stone HK, Kerecuk L, Gurgu M, Yousef Yengej FA, Ammerlaan CM, Rookmaaker MB, Hanna C, Rogers RC, Duran K, Peters E, Sayer JA, van Haaften G, Harris PC, Ling K, Mason JM, van Eerde AM, Steet R, Certain heterozygous variants in the kinase domain of the serine/threonine kinase NEK8 can cause an autosomal dominant form of polycystic kidney disease., *Kidney International* (2023), doi: <https://doi.org/10.1016/j.kint.2023.07.021>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Copyright © 2023, Published by Elsevier, Inc., on behalf of the International Society of Nephrology.

# Certain heterozygous variants in the kinase domain of the serine/threonine kinase NEK8 can cause an autosomal dominant form of polycystic kidney disease.

## Cohort




12 families  
- 21 individuals



Heterozygous *NEK8*  
variants

*Biallelic variants  
previously shown to  
cause syndromic  
ciliopathy*

## Methods




Clinical evaluation  
In silico assessment



In vitro investigation  
ciliogenesis, protein  
interactions, kinase  
function & DNA damage  
response

## Outcomes



Phenotype:


- polycystic kidney disease
- mostly early-onset kidney failure
- no consistent extra-renal features

## In vitro assays

- Variant Nek8 localizes to cilium
- Nek8 knockout IMCD3 cells expressing variant-bearing Nek8: decreased polycystin-2 in cilia & reduced kinase activity
- DNA damage signaling increased in patient derived tubuloids and Nek8 knockout IMCD3 cells
- Dominant-negative mechanism proposed



p.Arg45Trp recurrent in 10 families  
→ 6 *de novo* + 2 mosaic parents



Claus, 2023

## CONCLUSION

Heterozygous *NEK8* variants should be considered in genetic testing of children and adults with polycystic kidney disease

**[QUERY TO AUTHOR: title and abstract rewritten by Editorial Office – not subject to change]**

**Certain heterozygous variants in the kinase domain of the serine/threonine kinase NEK8 can cause an autosomal dominant form of polycystic kidney disease.**

Laura R Claus<sup>1a</sup>, Chuan Chen<sup>2a</sup>, Jennifer Stallworth<sup>3b,e</sup>, Joshua L Turner<sup>4b</sup>, Gisela Slaats<sup>5</sup>, Alexandra L Hawks<sup>4</sup>, Holly Mabillard<sup>6</sup>, Sarah R. Senum<sup>7</sup>, Sujata Srikanth<sup>3</sup>, Heather Flanagan-Steet<sup>3</sup>, Raymond J. Louie<sup>3</sup>, Josh Silver<sup>8,9</sup>, Jordan Lerner-Ellis<sup>9,10,11</sup>, Chantal Morel<sup>8,12</sup>, Chloe Mighton<sup>10,11</sup>, Frank Sleutels<sup>13</sup>, Marjon van Slegtenhorst<sup>13</sup>, Tjakko van Ham<sup>13</sup>, Alice S. Brooks<sup>13</sup>, Eiske M. Dorresteyn<sup>14</sup>, Tahsin Stefan Barakat<sup>13</sup>, Karin Dahan<sup>15</sup>, Nathalie Demoulin<sup>16,17</sup>, Eric Jean Goffin<sup>16,17</sup>, Eric Olinger<sup>6</sup>, Genomics England Research Consortium, Martin Larsen<sup>18</sup>, Jens Michael Hertz<sup>18</sup>, Marc R. Lilien<sup>19</sup>, Lena Obeidová<sup>20</sup>, Tomas Seeman<sup>21</sup>, Hillarey K Stone<sup>22</sup>, Larissa Kerecuk<sup>23</sup>, Mihai Gurgu<sup>24</sup>, Fjodor A Yousef Yengej<sup>25,26</sup>, Carola ME Ammerlaan<sup>25,26</sup>, Maarten B Rookmaaker<sup>25</sup>, Christian Hanna<sup>7,27</sup>, R. Curtis Rogers<sup>3</sup>, Karen Duran<sup>19</sup>, Edith Peters<sup>1</sup>, John A. Sayer<sup>6,28,29</sup>, Gijs van Haaften<sup>1c</sup>, Peter C. Harris<sup>2,7c</sup>, Kun Ling<sup>2d,f</sup>, Jennifer M. Mason<sup>4d,f</sup>, Albertien M. van Eerde<sup>1d,f</sup>, Richard Steet<sup>3d,f</sup>

1 University Medical Center Utrecht, Department of Genetics, Huispostnr KC.04.084.2, PO Box 85090 3508 AB Utrecht, Netherlands; email: avaneerde@umcutrecht.nl  
 2 Mayo Clinic, Department of Biochemistry and Molecular Biology, Rochester, MN, United States of America  
 3 Greenwood Genetic Center, 113 Gregor Mendel Circle, Greenwood, SC, United States of America; email: rsteet@ggc.org  
 4 Clemson University, Department of Genetics and Biochemistry, Clemson, SC, United States of America  
 5 Department of Nephrology and Hypertension, Regenerative Medicine Center Utrecht, University Medical Center Utrecht, Utrecht, The Netherlands  
 6 Newcastle University, Translational and Clinical Research Institute, Newcastle upon Tyne, United Kingdom  
 7 Mayo Clinic, Division of Nephrology and Hypertension, Rochester, MN, United States of America  
 8 Fred A. Litwin Family Centre in Genetic Medicine, Toronto, Canada  
 9 University of Toronto, Department of Molecular Genetics, Toronto, Canada  
 10 Mount Sinai Hospital, Pathology and Laboratory Medicine, Toronto, Canada  
 11 Lunenfeld-Tanenbaum Research Institute, Toronto, Canada  
 12 University of Toronto, Department of Medicine, Toronto, Canada  
 13 Department of Clinical Genetics, Erasmus MC University Medical Center, PO Box 2040, 3000 CA, Rotterdam, The Netherlands.  
 14 Department of Pediatric Nephrology, Erasmus University Medical Center, Sophia Children's Hospital, Rotterdam, the Netherlands  
 15 Institute Pathology and Genetic, Center of Human Genetics, Charleroi, Belgium  
 16 Cliniques Universitaires Saint-Luc, Division of Nephrology, Brussels, Belgium  
 17 Recherche Expérimentale et Clinique, UCLouvain, Brussels, Belgium  
 18 Odense University Hospital, Department of Clinical Genetics, and University of Southern Denmark, Department of Clinical Research, Odense, Denmark  
 19 Wilhelmina Children's Hospital (WKZ), Department of Pediatric Nephrology, Utrecht, Netherlands



20 Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles  
 University and General University Hospital in Prague, Czech Republic  
 21 Department of Pediatrics, 2<sup>nd</sup> Faculty of Medicine, Charles University Prague, Czech  
 Republic  
 22 Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical  
 Center, Cincinnati, OH, USA  
 23 Birmingham Women's and Children's NHS Foundation Trust, NIHR CRN West  
 Midlands, Birmingham, UK  
 24 Fundeni Clinical Institute, Bucharest, Romania  
 25 Department of Nephrology and Hypertension, University Medical Centre Utrecht,  
 Utrecht, the Netherlands  
 26 Hubrecht Institute for Developmental Biology and Stem Cell Research-KNAW,  
 Utrecht, Netherlands  
 27 Mayo Clinic, Division of Pediatric Nephrology and Hypertension, Rochester, MN,  
 United States of America  
 28 The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK  
 29 NIHR Biomedical Research Centre, Newcastle, UK

Co-corresponding senior authors:

Dr. Richard Steet, Director of Research, Greenwood Genetic Center, 113 Gregor  
 Mendel Circle, Greenwood, SC 29649, USA; email: [rsteet@ggc.org](mailto:rsteet@ggc.org)

Dr. Albertien van Eerde, Associate Professor of Translational Nephrogenetics,  
 University Medical Center Utrecht, Department of Genetics, House station no.  
 KC.04.084.2, PO Box 85090, 3508AB Utrecht, The Netherlands; email:  
[A.vanEerde@umcutrecht.nl](mailto:A.vanEerde@umcutrecht.nl)

Dr. Kun Ling, Professor, Division of Nephrology and Hypertension, Department of  
 Biochemistry and Molecular Biology, Mayo Clinic, 16-21 Guggenheim Building, 200 First  
 Street SW, Rochester, MN 55906, USA; email: [Ling.Kun@mayo.edu](mailto:Ling.Kun@mayo.edu)

Dr. Jennifer M. Mason, Assistant Professor, Department of Genetics and Biochemistry,  
 Clemson University, 154 Poole, 130 McGinty Court, Clemson, SC 29634, USA; email:  
[jmason4@clemson.edu](mailto:jmason4@clemson.edu)

a, b, c, d: equal contribution

e: former GGC employee, now employed by Sanofi

f: co-corresponding authors

g: deceased

Running Title: Heterozygous *NEK8* Variants Cause Polycystic Kidneys

Number of references: 46

Number of words in the abstract: 258

Number of words in the main text: 3959

Number of tables: 1

Number of figures: 4

Number of supplementary files: 1 (containing 3 supplemental figures and 1  
 supplemental table)

**Abstract:**

Autosomal dominant polycystic kidney disease (ADPKD) resulting from pathogenic variants in *PKD1* and *PKD2* is the most common form of PKD, but other genetic causes tied to primary cilia function have been identified. Biallelic pathogenic variants in the serine/threonine kinase *NEK8* cause a syndromic ciliopathy with extra-kidney manifestations. Here we identify *NEK8* as a disease gene for ADPKD in 12 families. Clinical evaluation was combined with functional studies using fibroblasts and tubuloids from affected individuals. *Nek8* knockout mouse kidney epithelial (IMCD3) cells transfected with wild type and variant *NEK8* were further used to study ciliogenesis, ciliary trafficking, kinase function, and DNA damage responses. Twenty-one affected monoallelic individuals uniformly exhibited cystic kidney disease (mostly neonatal) without consistent extra-kidney manifestations. Recurrent *de novo* mutations of the *NEK8* missense variant p.Arg45Trp, including mosaicism, were seen in ten families. Missense variants elsewhere within the kinase domain (p.Ile150Met and p.Lys157Gln) were also identified. Functional studies demonstrated normal localization of the NEK8 protein to the proximal cilium and no consistent cilia formation defects in patient-derived cells. NEK8-wild type protein or all variant forms of the protein expressed in *Nek8* knockout IMCD3 cells were localized to cilia and supported ciliogenesis. However, *Nek8* knockout IMCD3 cells expressing NEK8-p.Arg45Trp and NEK8-p.Lys157Gln showed significantly decreased polycystin-2 but normal protein ANKS6 localization in cilia. Moreover, p.Arg45Trp NEK8 exhibited reduced kinase activity *in vitro*. In patient derived tubuloids and IMCD3 cells expressing NEK8-p.Arg45Trp, DNA damage signaling was increased compared to healthy passage-matched controls. Thus, we propose a dominant-negative effect for specific heterozygous missense variants in the NEK8 kinase domain as a new cause of PKD.

**Keywords:**

*NEK8*, polycystic kidney disease, kinase, ciliopathy

**Lay Summary:**

Autosomal dominant polycystic kidney disease (ADPKD) is the most common form of polycystic kidney disease, but other genetic causes tied to primary cilia function have been identified. Heterozygous pathogenic variants in *NEK8* were identified in this study as the cause of an autosomal dominant form of PKD in 12 families. Clinical evaluation of patients with variants found within the *NEK8* kinase domain was combined with functional studies using fibroblasts and tubuloids from affected individuals, and mouse renal epithelial cells. The study proposes that these heterozygous missense variants act in a dominant-negative fashion to cause kidney disease. The findings further suggest that, *NEK8* should be included in gene panel testing for children and adults with PKD, and a causal relationship considered when heterozygous variants in the *NEK8* kinase domain are present.

## 1 Introduction:

2 Polycystic kidney diseases (PKD) are the most prevalent inherited kidney  
 3 diseases.<sup>1</sup> Autosomal dominant polycystic kidney disease (ADPKD), resulting from  
 4 pathogenic variants in *PKD1* and *PKD2*, is the most common form of PKD. This disease  
 5 usually presents in adulthood and often leads to kidney failure, with kidney failure with  
 6 replacement therapy (KFRT) typically needed in the 6<sup>th</sup> decade of life.<sup>2</sup> ADPKD-like  
 7 disease can also be caused by single rare variants in genes such as *GANAB*,  
 8 *DNAJB11*, *ALG5*, *ALG8*, *ALG9* and *IFT140*.<sup>3–8</sup> The disease is often more attenuated in  
 9 these patients, with KFRT rare. Autosomal recessive polycystic kidney disease  
 10 (ARPKD) is mostly caused by biallelic variants in *PKHD1*. The majority of patients  
 11 present in utero or in the neonatal period and often the disease progresses to KFRT  
 12 during childhood.<sup>9</sup>

13 PKD is mostly caused by pathogenic variants in genes encoding proteins with  
 14 roles in the functioning of primary cilia and therefore classified as a ciliopathy. Renal  
 15 ciliopathies can either present with an isolated kidney phenotype, or can have extensive  
 16 extra-renal characteristics, since primary cilia are present on nearly all cell types.<sup>9,10</sup>  
 17 Autosomal recessive inheritance is seen in many primary ciliopathies including  
 18 nephronophthisis, and Bardet-Biedl, Joubert, and Meckel-Gruber syndromes, with  
 19 multiple, often overlapping, monogenic causes. Autosomal dominant inheritance is rare  
 20 for ciliopathies, other than ADPKD(-like). Some syndromic ciliopathy genes have both  
 21 an autosomal recessive and autosomal dominant presentations, include *ZNF423*.<sup>11</sup> For  
 22 *IFT140* and *DNAJB11*, an autosomal recessive syndromic ciliopathy is seen in addition  
 23 to the ADPKD(-like) phenotype.<sup>5,12,13</sup> Similarly for *ALG8* and *ALG9*, autosomal recessive  
 24 inheritance results in congenital disorders of glycosylation (CDG), compared to the mild  
 25 ADPKD(-like) phenotype. Defective maturation and trafficking of the large PKD1 protein,  
 26 polycystin-1 (PC1), may be a common feature of many of the ADPKD-like diseases.<sup>3,4</sup>

27 Biallelic pathogenic variants in *NEK8* cause a syndromic ciliopathy with  
 28 multiorgan developmental defects; referred to as renal-hepatic-pancreatic dysplasia  
 29 (OMIM entry: 615415)<sup>14</sup> The *NEK8* protein is one of eleven ‘NEKs’, NimA (Never in  
 30 mitosis A)-related kinases, with roles in cell cycle control, DNA damage response and  
 31 other cell functions. In the kidney, *NEK8* is required for tubular integrity, thought to  
 32 regulate the renal tubule epithelial cell cytoskeletal structure, and is involved in ciliary  
 33 biogenesis/function. It forms a complex with ANKS6, INVS, and NPHP3. ANKS6 likely  
 34 coordinates the assembly of this complex, linking NPHP3 and INVS to *NEK8*, and  
 35 targets the complex to the proximal ciliary axoneme.<sup>15,16</sup> *NEK8* has been suggested to  
 36 interact with the polycystin signal transduction pathway, including regulating ciliary  
 37 protein targeting.<sup>17</sup> Functional studies have shown that biallelic *NEK8* variants affect  
 38 ciliogenesis, the DNA damage response, and epithelial morphogenesis.<sup>14</sup>

39 In this study we identified *NEK8* as a monoallelic disease gene in a large patient  
 40 cohort that included both recurrent *de novo*, mosaic, and inherited heterozygous *NEK8*  
 41 variants. We propose a dominant negative-effect for specific heterozygous *NEK8*  
 42 missense variants in the kinase domain.

## Materials and Methods:

### Patient enrollment and genomic analyses

Informed written consent was obtained, and is on file, from all patients or parents of the patients included in this study, and we adhered to all relevant ethical regulations at the respective institutions. Collaboration between centers was established through GeneMatcher.<sup>18</sup> Patients from the Genomics England 100,000 Genomes Project were enrolled as previously described (REC reference 14/EE/1112).<sup>19</sup> The procedures for sequencing, including coverage of *PKD1*, and variant filtering are described in the Supplementary Methods. The following transcripts were used in this study:

NM\_178170.2 (*NEK8*), NM\_000297.4 (*PKD2*), NM\_025114.4 (*CEP290*), NM\_001009944.2 (*PKD1*), NM\_024876.4 (*COQ8B*), and NM\_000322.5 (*PRPH2*).

### In silico predictions and structural modelling of *NEK8* variants

AlphaFold sequence AF-Q86SG6-F1 was imported to PyMOL and labelled according to available UniProtKB data due to lack of crystal structure. PyMOL Mutation Wizard was used to model the most likely structural impact of the variants for which AlphaFold produced a per-residue model confidence (pLDDT) >50. pLDDT is a measure for local accuracy of the model and is derived through the local Distance Difference Test (IDDT-C $\alpha$ ).<sup>20–22</sup> CADD scores were used for in silico predictions of the identified variants.<sup>23</sup> Furthermore, MetaDome's protein tolerance landscape was used to study genetic tolerance per amino acid position of the current and previous identified variants in the *NEK8* kinase domain.<sup>24</sup>

### Analyses of the function of *NEK8* in IMCD3 cells

**Antibodies and reagents:** Rabbit polyclonal antibodies: Arl13b (17711-1-AP, Proteintech); GPR161 (13398-1-AP, Proteintech); ANKS6 (HPA008355, Sigma); *NEK8* antibody is a kind gift from Dr. David Beier<sup>25</sup>; polycystin-2 antibody is provided by the Baltimore PKD Research and Clinical Core Center. Mouse monoclonal antibodies: acetylated  $\alpha$ -tubulin (T7451, Sigma), Myc-4A6 (05724, Sigma);  $\alpha$ -Tubulin (T6199, Sigma). Alexa Fluor-conjugated secondary antibodies are from Invitrogen. Primary antibodies were 1:1000 diluted for Western blot, and 1:500 diluted for immunofluorescence except for acetylated  $\alpha$ -tubulin.

**DNA constructs and CRISPR editing:** Full-length *NEK8* was amplified by PCR using the published *NEK8* plasmid as a template (pDONR223-*NEK8* was a gift from William Hahn & David Root (Addgene plasmid #23418; <http://n2t.net/addgene:23418>; RRID:Addgene\_23418)<sup>26</sup> and subcloned into the pcDNA3-myc vector. All *NEK8* variants were generated using a QuikChange site-directed mutagenesis kit (Agilent Technologies). The *Nek8* guide RNA (gRNA) was designed using an online tool (<https://zlab.bio/guide-design-resources>, TGTGCACCTGTGCCTGCGAA) and subcloned into pSpCas9(BB)-2A-GFP (px458). All constructs were verified by DNA sequencing. The px458-*Nek8* gRNA construct was transfected into IMCD3 cells as described.<sup>27</sup> Western blot, immunostaining and kinase assay details, as well as information about statistical analyses, are found in the Supplementary Methods.

### Human kidney tubuloid culture, cilia staining and assessment of DNA damage

Details on assessment of DNA damage and cilia staining in tubuloid cultures are described in the Supplementary Methods.<sup>26,27</sup>

#### Assessment of DNA damage

Fibroblast cells ( $2.5 \times 10^4$ ) were plated in 6-well plates containing 22x22 coverslips. After 48 h, cells were pulsed with 10  $\mu$ M EdU for 1 h, rinsed with 1X PBS, and treated with 0.5 mM hydroxyurea (MP Biomedical) for 6 h before fixation. Untreated controls were fixed immediately following the one-hour pulse with EdU. IMCD3 cells ( $4 \times 10^4$ ) were plated in a 12-well plate containing circular coverslips 24 h prior to fixation. Further detail on immunostaining and quantification is found in the Supplementary Methods.

## Results:

### Clinical details

A total of 21 individuals in twelve families with heterozygous *NEK8* variants and cystic kidney disease were identified through genetic testing, GeneMatcher<sup>18</sup>, or in one case in the published literature (**Figure 1** and **Supplementary Data**).<sup>28</sup> None of the families were known to be consanguineous, and screening did not reveal a (likely) pathogenic variant in any other PKD related gene. Clinical and genetic information is summarized in **Table 1**. The age of onset of kidney cysts was variable, with multiple cases diagnosed prenatally and the oldest individual diagnosed in the eighth decade. Initial clinical diagnoses included ARPKD, ADPKD, nephronophthisis, and focal segmental glomerulosclerosis (FSGS: based on biopsy in two patients). None of the patients showed the multiorgan involvement associated with *NEK8* biallelic disease. Ten families (14 individuals) had a recurrent variant in *NEK8* (c.133C>T, p.Arg45Trp) and these cases, except Family 10, had a consistent phenotype of enlarged kidneys, arterial hypertension, KFRT (before adulthood in non-mosaic cases), and absence of hepatic cysts. The proband from Family 10 had a milder phenotype with slightly enlarged kidneys and at 16 years normal kidney function. Short stature was noted in two of fourteen individuals (Family 7-III-3, Family 7-III-4) with the recurrent p.Arg45Trp variant. The proband with p.Lys157Gln in Family 12 had a comparable phenotype with prenatal onset of enlarged cystic kidneys, severe feeding difficulties, and KFRT at 4 years. Family 11 with p.Ile150Met had a later-onset presentation with only the oldest individual requiring dialysis in her 70s. Two of six individuals (III-1; IV-1) in this family had hypertension and liver cysts and one had borderline enlarged kidneys. No malignancies have been reported in the cohort of 21 cases.

In all affected individuals no second *NEK8* variant was detected after thorough testing. Three multiplex families illustrated affected parent-to-child transmission (**Figure 1a**), consistent with autosomal dominant inheritance, while in seven families the variant was *de novo*; in the remaining cases with a negative family history both parents were not available for screening. Interestingly, two families showed early onset chronic kidney disease in offspring heterozygous for the recurrent p.Arg45Trp variant, which was inherited from a mosaic parent who had later-onset chronic kidney disease (**Supplementary Figure S1**). **Supplementary Table S1** gives an overview of the genetic testing, including CNV and *PKD1* analysis, VUS interpretation, and ethnicity and consanguinity for all families.



## Imaging and pathology

Radiology findings from Families 3, 8 and 9 are shown in **Figure 1b-g**. Patients were found to have enlarged kidneys with numerous cysts. In Family 9 CT analysis of the mosaic grandmother at age 48 years old (**Figure 1e**) and the proband at age 23 months and 5 years old (**Figure 1f, 1g**) showed enlarged cystic kidneys. Gross and histological analysis of kidneys after bilateral nephrectomy in patients from Families 4, 8, and 12 showed multiple larger tubular and glomerular cysts (**Figure 1i-l**).

## Summary of variants

All three monoallelic *NEK8* variants in this study were missense alterations in the kinase domain. In contrast, variants associated with biallelic disease are found in all parts of the gene/protein, including the kinase domain (**Figure 2a**). None of the variants are present in the gnomAD database that contains more than 140,000 unrelated individuals without known severe pediatric disease.<sup>29</sup> The substitutions affect evolutionary conserved residues, and prediction tools predict a damaging effect (**Figure 2b-d**). The Protein Tolerance Landscape of *NEK8* shows that most missense variants lie in a relatively intolerant region of the enzyme, with the notable exception of the p.Thr87Ala alteration previously identified in the biallelic cases (**Figure 2b**). CADD scores for the three variants studied here predict a significant functional defect and all had a frequency of 0 in gnomAD (**Figure 2c**). The amino acid positions of these variants are highly conserved across species (**Figure 2d**).

## Structural protein modeling

*NEK8* contains an N-terminal kinase domain and C-terminal 'Regulator of Chromosome Condensation 1' (RCC1) domains (**Figure 2a, e inset a.**). The RCC1 domains are guanine nucleotide exchange factor (GEF) for the GTP-binding protein Ran and feature a 7-bladed propellor of beta-strands. *NEK8* also contains a coiled-coil domain within the protein's C-terminus thought to be involved in protein-protein interactions. *NEK8* is proposed to be auto-phosphorylated at position Thr-210 on the protein kinase domain, followed by phosphorylation occurring at other sites in the molecule. The protein kinase domain also features ATP binding sites and a proton acceptor site.<sup>30</sup> The *NEK8* variants with high quality structural data (pLDDT > 50) were p.Arg45Trp and p.Ile150Met (**Figure 2e, inset b. and c.**, respectively). The dashed black lines demonstrate likely loss of the canonical geometry between 2 atoms in this loop with overlap of each (numerically labelled in angstroms). The red discs represent significant pairwise overlap of atomic van der Waals radii causing a likely structural 'clash'. The amino acid volume change in the missense variant p.Arg45Trp (**inset b.**) is large (190.3 to 226.4 angstroms) with a very small volume change of 163.0 to 165.8 angstroms in missense variant p.Ile150Met (**inset c.**).<sup>31</sup> The two variants are positioned in adjacent alpha-helices (**inset d.**). Although the crystal structure of the third variant p.Lys157Gln could not be predicted due to a low confidence score, the variant appears to be in close proximity to the others as highlighted by the arrow (**inset d.,3**).

## Analyses of the *NEK8* monoallelic variants

To understand the functionality of NEK8 in renal epithelial cells, we inactivated *Nek8* in IMCD3 cells using CRISPR/Cas9 (**Figure 3a**), and then re-expressed the Myc-tagged wild-type (WT) or one of the monoallelic variants of human NEK8 in these *Nek8*<sup>-/-</sup> cells. Two other NEK8 mutations in the kinase domain were also included for comparison. One is the approved kinase-dead (KD) mutation p.Lys33Met that was designed based on structural analysis.<sup>32</sup> The other is p.Thr87Ala that was found in compound heterozygosity with p.Arg602Trp in a patient with the typical recessive phenotype.<sup>14</sup> Immunoblotting showed that the overall expression and stability of these NEK8 mutants were comparable to their wild-type counterpart (**Figure 3b**), and all mutated NEK8 proteins exhibited a similar incorporation rate and localization pattern in cilia as NEK8-WT (**Figure 3c**). Compared to parental cells, IMCD3 cells with or without expression of endogenous *Nek8* or exogenous NEK8 variants displayed a similar percentage of ciliated cells, which are represented by staining with the ciliary membrane marker ARL13B (**Figure 3d**, upper panel). However, primary cilia in *Nek8*<sup>-/-</sup> cells were significantly truncated, which was rescued equally well by NEK8-WT or NEK8-KD (p.Lys33Met) (**Figure 3d**, lower panel), indicating that the kinase activity of NEK8 is not required for the assembly of primary cilia. Re-expression of p.Arg45Trp, p.Thr87Ala, or p.Ile150Met also significantly rescued the cilia length, although for p.Thr87Ala and p.Ile150Met the length was less than for the WT rescue, whereas NEK8-K157Q failed to correct the cilia length defect. These data are consistent with our findings in patients' fibroblasts which expressed a monoallelic variant and the wildtype allele, that the overall structure of cilia is not affected by p.Arg45Trp and p.Ile150Met (**Supplementary Figure S2a-c**), but cilia are shortened by p.Lys157Gln (**Supplementary Figure S2d-e**). Consistent with the reported role of NEK8 in recruiting ANKS6 to the inversin compartment,<sup>16</sup> ANKS6 was undetectable in cilia in *Nek8*<sup>-/-</sup> cells (**Figure 3e**). The recruitment of ANKS6 to cilia was fully recovered by expressing either NEK8-WT or any of the disease variants, but was only rescued to ~30% by p.Lys33Met, the KD mutant (**Figure 3e**).

When we examined GPR161, a cilium-residing G protein-coupled receptor, we found that its ciliary localization was similar with or without NEK8 and was not affected by the expression of any tested NEK8 mutants (**Figure 3f**). However, knockout of *Nek8* strongly suppressed the ciliary level of polycystin-2 (PC2), the product of *PKD2* (**Figure 3g**). The ciliary targeting of PC2 in *Nek8*-null cells was fully recovered by re-expressing NEK8-WT, as well as p.Thr87Ala and p.Ile150Met (**Figure 3g**), while p.Lys33Met and p.Lys157Gln only partially rescued PC2 in cilia. Interestingly, NEK8-p.Arg45Trp completely failed to recover the ciliary level of PC2 in *Nek8*<sup>-/-</sup> cells (**Figure 3g**). Yet, the total protein level of PC2 appeared comparable in IMCD3 cells expressing endogenous *Nek8* or exogenous NEK8 variants (**Figure 3h**). These results suggest that in addition to supporting the assembly of cilia, NEK8 plays a unique role in maintaining the ciliary homeostasis of PC2, and the p.Arg45Trp variant specifically loses this capability. Consistently, fibroblast cells from two patients carrying p.Arg45Trp also exhibited less PC2 in cilia compared to normal fibroblasts (**Figure 3i**). The PC2 trafficking phenotype in the patient fibroblasts was less severe, however, compared to the IMCD3 cells expressing the variant *Nek8*, likely because the fibroblasts still have one wild type allele, whereas the IMCD3 cells are *Nek8*-null and fully expressing NEK8-p.Arg45Trp.

Since p.Arg45Trp is in the kinase domain, we also determined the autophosphorylation of NEK8. Myc-tagged NEK8-WT and NEK8-p.Arg45Trp were overexpressed in 293T cells and immunoprecipitated (IP) by an anti-Myc antibody and Protein-G Sepharose beads. The phosphorylated and non-phosphorylated NEK8 proteins were then separated by Phos-tag SDS-PAGE<sup>33</sup> and detected by immunoblotting. As shown in **Figure 3j**, the autophosphorylation level of NEK8-p.Arg45Trp was significantly lower than NEK8-WT, suggesting that p.Arg45Trp partially loses kinase activity.

### Assessment of DNA damage response

NEK8 is a regulator of DNA damage response and NEK8-deficient cells exhibit increased DNA damage<sup>14</sup>. We examined the DNA damage response in IMCD3 cells by staining cells with histone H2AX phosphorylated at Serine 319,  $\gamma$ H2AX, a marker of DNA damage that occurs at double strand breaks and stalled replication forks.<sup>34–36</sup> Compared to the parental IMCD3 cells, NEK8 KO cells had a significant increase in  $\gamma$ H2AX (**Figure 4a**). Expression of NEK8-WT, but not NEK8-p.Arg45Trp in the *Nek8*<sup>-/-</sup> cells rescued  $\gamma$ H2AX accumulation in IMCD3 cells, indicating that partial disruption of the kinase activity results in DNA damage response activation. Next, we examined  $\gamma$ H2AX accumulation in cell lines derived from patients. In patient derived tubuloids from Family 12, heterozygous for p.Lys157Gln, we found an increase in  $\gamma$ H2AX compared to three healthy passage-matched controls (**Figure 4b**).

In patient-derived fibroblasts, we pulsed cells with EdU to identify S phase cells and  $\gamma$ H2AX in EdU-positive cells. In NEK8-deficient cells,  $\gamma$ H2AX accumulation occurs primarily in S phase.<sup>35</sup> However, we did not detect a significant difference in  $\gamma$ H2AX between control, p.Arg45Trp or p.Ile150Met fibroblasts (**Supplementary Figure S3**). Treatment of NEK8-deficient cells with replication stress inducing drugs leads to a further increase in  $\gamma$ H2AX.<sup>37</sup> We determined if treating patient fibroblasts with the replication inhibiting drug, hydroxyurea, would lead to an increase in  $\gamma$ H2AX activation. In control fibroblasts, hydroxyurea resulted in a significant increase in  $\gamma$ H2AX staining intensity indicating activation of the DNA damage response, but this response was similar in p.Arg45Trp or p.Ile150Met fibroblasts (**Supplementary Figure S3**).

### **Discussion:**

Here we present evidence of monoallelic disease in twelve families associated with three distinct heterozygous *NEK8* variants within the kinase domain. Biallelic *NEK8* variants cause severe multiorgan developmental defects including renal cystic dysplasia, with primary cilia formation, DNA damage responses, and epithelial morphogenesis implicated.<sup>14</sup> Biallelic variants are loss-of-function (LOF) or missense changes that do not have a known phenotypic effect in heterozygous carriers.<sup>14</sup> In our families monoallelic inheritance is supported by the demonstrated *de novo* variants and autosomal dominant inheritance in multiplex families. Assessment of the Protein Tolerance Landscape shows that all three missense variants in this study exist in intolerant regions of the protein (**Figure 2b**). We believe these variants have a dominant-negative effect, explaining the severe phenotype associated with a single



variant. Another distinction of the monoallelic disease is that all the affected individuals primarily have renal phenotypes.

None of the monoallelic variants are present in gnomAD, which contrasts with the previously reported recessive variants for which most can be found as heterozygotes in this database.<sup>29</sup> While the genetic tests that were performed differed between the families, whole exome sequencing was completed in at least one individual for every distinct variant (**Supplementary Table S1**). *PKD1* analysis, complicated by the *PKD1* pseudogenes<sup>38</sup>, also differed between families, but long-range PCR and Sanger analysis was performed in at least six patients. Variants of unknown significance in other genes identified in some individuals were interpreted as likely non-causal (**Supplementary Table S1**). All encountered monoallelic variants were located in the kinase domain, while biallelic, disease-causing variants can be present throughout the gene. Presently, there are not consistent genotype-phenotype correlations for biallelic *NEK8* variants.<sup>14,15,37-41</sup> In contrast, the kidney phenotype associated with *NEK8*-p.Arg45Trp and p.Lys157Gln was largely consistent, with enlarged kidneys in infants and limited extra-renal disease, while the p.Ile150Met phenotype was considerably milder.

The monoallelic *NEK8* phenotype can be clinically mistaken for either ARPKD or ADPKD. The early onset PKD seen with the p.Arg45Trp and p.Lys157Gln variants, and the childhood kidney failure and requirement for bilateral nephrectomies (5 out of 21 in our cohort), overlaps with ARPKD, although very early onset has been reported in ~1% of ADPKD cases, but often because of biallelic disease.<sup>42</sup> The inheritance pattern and localization of cysts in all parts of the nephron (shown in two patients) is more consistent with ADPKD.<sup>42</sup> An unusual aspect is the high level of *de novo* mutations of p.Arg45Trp, similar to whole gene deletions of *HNF1B*, and recurrent mosaic presentation associated with milder disease. A recent case report also described a *de novo* p.Arg45Trp variant in a 2-year old patient with infantile nephronophthisis which was characterized by multicystic kidney dysplasia and progressive renal failure.<sup>43</sup> There is possible CpG methylation at this site; methylated CpG dinucleotides are more likely to deaminate than other cytosines, making them mutational hot spots.<sup>44,45</sup> It will be interesting to see the diagnostic yield of monoallelic *NEK8* using genotype first approaches in infantile PKD cohorts.

Functional studies using *Nek8* knockout IMCD3 cells identified shorter cilia and defects in the localization of ANKS6 and PC2 to cilia, as previously reported.<sup>17</sup> When these cells were transfected with *NEK8*-WT or the monoallelic *NEK8* variants, both *NEK8* and ANKS6 localized to the proximal cilium and the cilia length defect was wholly or partially corrected, except for shorter cilia in p.Lys157Gln. However, PC2 localization to the primary cilium was only rescued by re-expressing *NEK8*-WT, not *NEK8*-p.Arg45Trp or p.Lys157Gln. The effect of PC2 localization but not some other ciliary components may provide a clue to the cystic kidney specific phenotype we see in the monoallelic cases. Changes at certain positions within the kinase domain with unique functional consequences appear to be crucial. The kinase dead variant, p.Lys33Met had defects in both ANKS6 and PC2 localization. However, a described recessive kinase variant, P.Thr87Ala did not have localization defects for ANKS6 or PC2. This may be because it is a hypomorphic allele (it lies in a highly tolerant region as shown by

structural protein modeling) and any defect may be too subtle for our functional assay to detect.

We believe a dominant-negative effect is the most likely disease mechanism. We propose that this dominant-negative effect includes binding of monoallelic mutant NEK8 to wildtype NEK8, and likely other members of the ANKS6 complex, resulting in a complex that is nonfunctional for PC2 trafficking. This will result in a greater than the 50% loss of PC2 in cilia associated with a LOF variant. Our experimental re-expression system is not well suited to analyze interactions between alleles, but we note in cells from two patients heterozygous for p.Arg45Trp a significantly lower level of PC2 in cilia than in normal cells, possibly showing an inactivating interaction with the normal allele.

The location of the variants in the *NEK8* kinase domain indicates a mechanism of action related to phosphorylation; NEK8 is known to have autophosphorylation activity.<sup>30</sup> With our kinase assay in *Nek8* knockout cells transfected with NEK8-p.Arg45Trp we showed a decrease of autophosphorylated NEK8, indicating that kinase function is impacted by this variant. In the juvenile cystic kidney (*jck*) mouse model, due to a homozygous *Nek8* missense variant, abnormal phosphorylation of PC2 was detected which was associated with longer cilia and ciliary accumulation of PC1 and PC2.<sup>17</sup> This contrasts to our findings with p.Arg45Trp of normal length but defective ciliary trafficking of PC2, indicating a more specific kinase defect.

We acknowledge several limitations within the present study. We have developed an exogenous expression system for *NEK8* variants in a null *Nek8* background that has illustrated differences in cilia protein localizations between p.Arg45Trp and p.Lys157Gln and the null cells and a kinase dead mutation. So far because of available constructs/antibodies our analysis has been limited to PC2, but including PC1 and the ARPKD protein, fibrocystin, would also be interesting. In our exogenous expression assay, weaker monoallelic and biallelic variants were not fully informative, likely reflecting its sensitivity and that it is only an approximation of the in vivo situation. A cilia length defect was also detected for p.Lys157Gln but not the other monoallelic variants, suggesting a possible different mode of action that we do not yet fully understand. Patient cells and tubuloid systems were helpful but were not always consistent in their readout, probably because the effects are likely dependent on both cell type and expression level. For example, NEK-pArg45Trp failed to restore DNA damage responses in the IMCD3 cells but no increase in  $\gamma$ H2AX staining was observed in the patient fibroblasts. One possibility is the difference in proliferation rates between the two cell lines can be leading to a difference in the replication stress response. A complete understanding of how each missense variant alters kinase function and/or substrate recognition will require longer-term investigation, including the generation of mammalian animal models, phosphoproteomic studies, and the comparative analysis of these variants with the other missense variants identified in the biallelic patients.

To conclude, here we present evidence for a pathogenic effect of specific heterozygous *NEK8* variants, provide a new mode of inheritance for *NEK8* variants, and expand the phenotype associated with variants in this gene. Heterozygous *NEK8* variants within the kinase domain should be considered in patients with infantile PKD. For children and adults with PKD, we suggest *NEK8* should be included in gene panel testing and heterozygous variants in the kinase domain evaluated for causality.

## Declaration of interests

The authors declare no competing interests. Jennifer Stallworth completed this work as an employee at GGC, and is now a Sanofi employee.

## Acknowledgments

We thank the study participants and their families for their contribution. The full list of funding information and acknowledgements is found in the Supplementary file.

**The Genomics England Research Consortium:** John C. Ambrose<sup>1</sup>; Prabhu Arumugam<sup>1</sup>; Roel Bevers<sup>1</sup>; Marta Bleda<sup>1</sup>; Freya Boardman-Pretty<sup>1,2</sup>; Christopher R. Boustred<sup>1</sup>; Helen Brittain<sup>1</sup>; Mark J. Caulfield<sup>1,2</sup>; Georgia C. Chan<sup>1</sup>; Greg Elgar<sup>1,2</sup>; Tom Fowler<sup>1</sup>; Adam Giess<sup>1</sup>; Angela Hamblin<sup>1</sup>; Shirley Henderson<sup>1,2</sup>; Tim J. P. Hubbard<sup>1</sup>; Rob Jackson<sup>1</sup>; Louise J. Jones<sup>1,2</sup>; Dalia Kasperaviciute<sup>1,2</sup>; Melis Kayikci<sup>1</sup>; Athanasios Kousathanas<sup>1</sup>; Lea Lahnstein<sup>1</sup>; Sarah E. A. Leigh<sup>1</sup>; Ivonne U. S. Leong<sup>1</sup>; Javier F. Lopez<sup>1</sup>; Fiona Maleady-Crowe<sup>1</sup>; Meriel McEntagart<sup>1</sup>; Federico Minneci<sup>1</sup>; Loukas Moutsianas<sup>1,2</sup>; Michael Mueller<sup>1,2</sup>; Nirupa Murugaesu<sup>1</sup>; Anna C. Need<sup>1,2</sup>; Peter O'Donovan<sup>1</sup>; Chris A. Odhams<sup>1</sup>; Christine Patch<sup>1,2</sup>; Mariana Buongiorno Pereira<sup>1</sup>; Daniel Perez-Gil<sup>1</sup>; John Pullinger<sup>1</sup>; Tahrima Rahim<sup>1</sup>; Augusto Rendon<sup>1</sup>; Tim Rogers<sup>1</sup>; Kevin Savage<sup>1</sup>; Kushmita Sawant<sup>1</sup>; Richard H. Scott<sup>1</sup>; Afshan Siddiq<sup>1</sup>; Alexander Sieghart<sup>1</sup>; Samuel C. Smith<sup>1</sup>; Alona Sosinsky<sup>1,2</sup>; Alexander Stuckey<sup>1</sup>; Mélanie Tanguy<sup>1</sup>; Ana Lisa Taylor Tavares<sup>1</sup>; Ellen R. A. Thomas<sup>1,2</sup>; Simon R. Thompson<sup>1</sup>; Arianna Tucci<sup>1,2</sup>; Matthew J. Welland<sup>1</sup>; Eleanor Williams<sup>1</sup>; Katarzyna Witkowska<sup>1,2</sup>; Suzanne M. Wood<sup>1,2</sup>.  
 1. Genomics England, London, UK  
 2. William Harvey Research Institute, Queen Mary University of London, London, EC1M 6BQ, UK.

## URLs

CADD, <https://cadd.gs.washington.edu>  
 Metadome, <https://stuart.radboudumc.nl/metadome/about>  
 dbSNP, <https://www.ncbi.nlm.nih.gov/snp/>  
 gnomAD, <http://gnomad.broadinstitute.org/>  
 AlphaFold, <https://alphafold.ebi.ac.uk>  
 PyMOL, <https://pymol.org/2/>  
 ClinVar, <https://www.ncbi.nlm.nih.gov/clinvar/>

## Supplementary Files

Supplementary Data: clinical details families  
 Supplementary Figure S1: mosaicism in parent of later-onset case  
 Supplementary Table S1: genetic testing overview + details on ethnicity and consanguinity  
 Supplementary Figure S2: NEK8 localization and ciliation in cells from affected individuals  
 Supplementary Figure S3: DNA damage response in patient-derived fibroblasts

## References

1. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. *The Lancet*. 2007;369(9569):1287-1301. doi:https://doi.org/10.1016/S0140-6736(07)60601-1
2. Shaw C, Simms RJ, Pitcher D, Sandford R. Epidemiology of patients in England and Wales with autosomal dominant polycystic kidney disease and end-stage renal failure. *Nephrol Dial Transplant*. 2014;29(10):1910-1918. doi:10.1093/ndt/gfu087
3. Besse W, Dong K, Choi J, et al. Isolated polycystic liver disease genes define effectors of polycystin-1 function. *J Clin Invest*. 2017;127(5):1772-1785. doi:10.1172/JCI90129
4. Besse W, Chang AR, Luo JZ, et al. ALG9 Mutation Carriers Develop Kidney and Liver Cysts. *J Am Soc Nephrol*. 2019;30(11):2091-2102. doi:10.1681/ASN.2019030298
5. Senum SR, Li YSM, Benson KA, et al. Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype. *Am J Hum Genet*. 2022;109(1):136-156. doi:10.1016/j.ajhg.2021.11.016
6. Cornec-Le Gall E, Olson RJ, Besse W, et al. Monoallelic Mutations to DNAJB11 Cause Atypical Autosomal-Dominant Polycystic Kidney Disease. *Am J Hum Genet*. 2018;102(5):832-844. doi:10.1016/j.ajhg.2018.03.013
7. Porath B, Gainullin VG, Cornec-Le Gall E, et al. Mutations in GANAB, Encoding the Glucosidase II $\alpha$  Subunit, Cause Autosomal-Dominant Polycystic Kidney and Liver Disease. *Am J Hum Genet*. 2016;98(6):1193-1207. doi:10.1016/j.ajhg.2016.05.004
8. Lemoine H, Raud L, Foulquier F, et al. Monoallelic pathogenic ALG5 variants cause atypical polycystic kidney disease and interstitial fibrosis. *Am J Hum Genet*. 2022;109(8):1484-1499. doi:10.1016/J.AJHG.2022.06.013
9. Waters AM, Beales PL. Ciliopathies: An expanding disease spectrum. *Pediatric Nephrology*. 2011;26(7):1039-1056. doi:10.1007/s00467-010-1731-7
10. Hildebrandt F, Benzing T, Katsanis N. Ciliopathies. *New England Journal of Medicine*. 2011;364(16):1533-1543. doi:10.1056/nejmra1010172
11. Chaki M, Airik R, Ghosh AK, et al. Exome capture reveals ZNF423 and CEP164 mutations, linking renal ciliopathies to DNA damage response signaling. *Cell*. 2012;150(3):533-548. doi:10.1016/j.cell.2012.06.028
12. Ateş EA, Turkyilmaz A, Delil K, et al. Biallelic Mutations in DNAJB11 Are Associated with Prenatal Polycystic Kidney Disease in a Turkish Family. Vol 12. *Mol Syndromol*; 2021:179-185. doi:10.1159/000513611
13. Jordan P, Arrondel C, Bessières B, et al. Bi-allelic pathogenic variations in DNAJB11 cause Ivemark II syndrome, a renal-hepatic-pancreatic dysplasia. *Kidney Int*. 2021;99(2):405-409. doi:10.1016/J.KINT.2020.09.029
14. Grampa V, Delous M, Zaidan M, et al. Novel NEK8 Mutations Cause Severe Syndromic Renal Cystic Dysplasia through YAP Dysregulation. *PLoS Genet*. 2016;12(3):e1005894. doi:10.1371/journal.pgen.1005894

- 1 15. Frank V, Habbig S, Bartram MP, et al. Mutations in NEK8 link multiple organ  
2 dysplasia with altered Hippo signalling and increased c-MYC expression. *Hum*  
3 *Mol Genet.* 2013;22(11):2177-2185. doi:10.1093/hmg/ddt070
- 4 16. Hoff S, Halbritter J, Epting D, et al. ANKS6 is a central component of a  
5 nephronophthisis module linking NEK8 to INVS and NPHP3. *Nat Genet.*  
6 2013;45(8):951-956. doi:10.1038/ng.2681
- 7 17. Sohara E, Luo Y, Zhang J, Manning DK, Beier DR, Zhou J. Nek8 regulates the  
8 expression and localization of polycystin-1 and polycystin-2. *Journal of the*  
9 *American Society of Nephrology.* 2008;19(3):469-476.  
10 doi:10.1681/ASN.2006090985
- 11 18. Sobreira N, Schiettecatte F, Valle D, Hamosh A. GeneMatcher: A Matching Tool  
12 for Connecting Investigators with an Interest in the Same Gene. *Hum Mutat.*  
13 2015;36(10):928-930. doi:10.1002/humu.22844
- 14 19. Smedley D, Smith KR, Martin A, et al. 100,000 Genomes Pilot on Rare-Disease  
15 Diagnosis in Health Care - Preliminary Report. *N Engl J Med.* 2021;385(20):1868-  
16 1880. doi:10.1056/NEJMOA2035790
- 17 20. Varadi M, Anyango S, Deshpande M, et al. AlphaFold Protein Structure  
18 Database: massively expanding the structural coverage of protein-sequence  
19 space with high-accuracy models. *Nucleic Acids Res.* 2022;50(D1):D439-D444.  
20 doi:10.1093/NAR/GKAB1061
- 21 21. Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction  
22 with AlphaFold. *Nature* 2021 596:7873. 2021;596(7873):583-589.  
23 doi:10.1038/s41586-021-03819-2
- 24 22. Mariani V, Biasini M, Barbato A, Schwede T. IDDT: a local superposition-free  
25 score for comparing protein structures and models using distance difference tests.  
26 *Bioinformatics.* 2013;29(21):2722. doi:10.1093/BIOINFORMATICS/BTT473
- 27 23. Rentzsch P, Schubach M, Shendure J, Kircher M. CADD-Splice—improving  
28 genome-wide variant effect prediction using deep learning-derived splice scores.  
29 *Genome Med.* 2021;13(1). doi:10.1186/s13073-021-00835-9
- 30 24. Wiel L, Baakman C, Gilissen D, Veltman JA, Vriend G, Gilissen C. MetaDome:  
31 Pathogenicity analysis of genetic variants through aggregation of homologous  
32 human protein domains. *Hum Mutat.* 2019;40(8):1030-1038.  
33 doi:10.1002/humu.23798
- 34 25. Manning DK, Sergeev M, van Heesbeen RG, et al. Loss of the ciliary kinase Nek8  
35 causes left-right asymmetry defects. *J Am Soc Nephrol.* 2013;24(1):100-112.  
36 doi:10.1681/ASN.2012050490
- 37 26. Johannessen CM, Boehm JS, Kim SY, et al. COT/MAP3K8 drives resistance to  
38 RAF inhibition through MAP kinase pathway reactivation. *Nature.*  
39 2010;468(7326):968. doi:10.1038/NATURE09627
- 40 27. Chen C, Xu Q, Zhang Y, et al. Ciliopathy protein HYLS1 coordinates the  
41 biogenesis and signaling of primary cilia by activating the ciliary lipid kinase  
42 PIPKly. *Sci Adv.* 2021;7(26). doi:10.1126/SCIADV.ABE3401
- 43 28. Obeidova L, Seeman T, Fencel F, et al. Results of targeted next-generation  
44 sequencing in children with cystic kidney diseases often change the clinical  
45 diagnosis. *PLoS One.* 2020;15(6):e0235071.



29. Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature*. 2020;581(7809):434-443. doi:10.1038/s41586-020-2308-7
30. Holland PM, Milne A, Garka K, et al. Purification, cloning, and characterization of Nek8, a novel nima-related kinase, and its candidate substrate Bicd2. *Journal of Biological Chemistry*. 2002;277(18):16229-16240. doi:10.1074/jbc.M108662200
31. Tsai J, Gerstein M. Calculations of protein volumes: Sensitivity analysis and parameters database. *Bioinformatics*. 2002;18(7):985-995. doi:10.1093/bioinformatics/18.7.985
32. Czarnecki PG, Gabriel GC, Manning DK, et al. ANKS6 is the critical activator of NEK8 kinase in embryonic situs determination and organ patterning. *Nat Commun*. 2015;6. doi:10.1038/ncomms7023
33. Kinoshita E, Kinoshita-Kikuta E, Koike T. Separation and detection of large phosphoproteins using Phos-tag SDS-PAGE. *Nat Protoc*. 2009;4(10):1513-1521. doi:10.1038/NPROT.2009.154
34. Helt CE, Cliby WA, Keng PC, Bambara RA, O'Reilly MA. Ataxia telangiectasia mutated (ATM) and ATM and Rad3-related protein exhibit selective target specificities in response to different forms of DNA damage. *J Biol Chem*. 2005;280(2):1186-1192. doi:10.1074/JBC.M410873200
35. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. *J Biol Chem*. 1998;273(10):5858-5868. doi:10.1074/JBC.273.10.5858
36. Ward IM, Chen J. Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress. *J Biol Chem*. 2001;276(51):47759-47762. doi:10.1074/JBC.C100569200
37. Choi HJC, Lin JR, Vannier JB, et al. NEK8 Links the ATR-Regulated Replication Stress Response and S Phase CDK Activity to Renal Ciliopathies. *Mol Cell*. 2013;51(4):423-439. doi:https://doi.org/10.1016/j.molcel.2013.08.006
38. Ali H, Al-Mulla F, Hussain N, et al. PKD1 Duplicated regions limit clinical Utility of Whole Exome Sequencing for Genetic Diagnosis of Autosomal Dominant Polycystic Kidney Disease. *Sci Rep*. 2019;9(1):4141. doi:10.1038/s41598-019-40761-w
39. Rajagopalan R, Grochowski CM, Gilbert MA, et al. Compound heterozygous mutations in NEK8 in siblings with end-stage renal disease with hepatic and cardiac anomalies. *Am J Med Genet A*. 2016;170(3):750-753. doi:10.1002/AJMG.A.37512
40. Otto EA, Trapp ML, Schultheiss UT, Helou J, Quarmby LM, Hildebrandt F. NEK8 mutations affect ciliary and centrosomal localization and may cause nephronophthisis. *J Am Soc Nephrol*. 2008;19(3):587-592. doi:10.1681/ASN.2007040490
41. Domingo-Gallego A, Pybus M, Bullich G, et al. Clinical utility of genetic testing in early-onset kidney disease: seven genes are the main players. *Nephrology, dialysis, transplantation*. 2022;37(4):687-696. doi:10.1093/NDT/GFAB019
42. Bergmann C. ARPKD and early manifestations of ADPKD: the original polycystic kidney disease and phenocopies. *Pediatr Nephrol*. 2015;30(1):15-30. doi:10.1007/s00467-013-2706-2

- 1 43. Mehawej C, Chouery E, Ghabril R, Tokajian S, Megarbane A. NEK8-Associated  
2 Nephropathies: Do Autosomal Dominant Forms Exist? *Nephron*. Published online  
3 2022. doi:10.1159/000526841
- 4 44. Kent WJ, Sugnet CW, Furey TS, et al. The human genome browser at UCSC.  
5 *Genome Res*. 2002;12(6):996-1006. doi:10.1101/GR.229102
- 6 45. Cooper DN, Mort M, Stenson PD, Ball E V., Chuzhanova NA. Methylation-  
7 mediated deamination of 5-methylcytosine appears to give rise to mutations  
8 causing human inherited disease in CpNpG trinucleotides, as well as in CpG  
9 dinucleotides. *Hum Genomics*. 2010;4(6):406-410. doi:10.1186/1479-7364-4-6-  
10 406  
11  
12  
13

## Legends to the Figures

**Figure 1. Pedigrees and polycystic kidney images |** **a.** pedigrees of twelve families with heterozygous *NEK8* variants. Solid symbols indicate affected individual with kidney disease. Arrow indicates proband. +/- indicates presence of heterozygous *NEK8* variant. -/- indicate biallelic wildtype *NEK8*. Roman numerals indicate generation. MZ = monozygotic; d. death. **b.** MRI images of proband of Family 3 at age 16: enlarged kidney with multiple cysts, total kidney volume 1300 ml. **c-d.** Ultrasound of proband of Family 8: enlarged kidneys with extensive bilateral kidney cysts. At age 2 right kidney measured 13.6 cm and left kidney measured 13.3 cm (**c**), at age 7 right kidney: 17.5 cm and left kidney: 17.7 cm (**d**). **e-g.** CT analysis of Family 9: bilaterally enlarged kidneys with cysts. **e.** CT at 48 years of II-2, who is mosaic for the *NEK8* variant. **f-g.** CT of proband IV-1 at 23 months (**f**) and at 5 years old (**g**). **h.** Pathology images of right kidney of proband of Family 4 at age 5 (20 x 11 x 10 cm, 1488 grams). **i.** Pathology images of right kidney of proband of Family 8 at 7 years old. **j.** Pathology images of left kidney of proband of Family 12 at age 4 (18 x 8 x 9.5 cm). **k.** Hematoxylin and eosin stain of proband of Family 8 showed multiple larger tubular cysts, with glomerular cysts also noted. **l.** Hematoxylin and eosin stain of proband of Family 12 shows multiple cysts both glomerular and tubular. Below the capsule cysts are smaller and they are larger at the corticomedullary junction. Some fibrosis is seen towards the medulla.

**Figure 2. Position of variants and domain organization of the NEK8 protein.** **a.** In red novel heterozygous variants described in this paper. In black variants previously published in biallelic cases. **b.** Protein Tolerance Landscape with identified variants and previously reported missense variants in kinase domain highlighted. Color coding indicates predicted impact of variant on protein function with blue =most tolerant, yellow= neutral, red=most detrimental. **c.** In silico predictions of the novel heterozygous *NEK8* variants. **d.** Multiple sequence alignment of the human *NEK8* full protein zoomed in on well conserved kinase domain. The amino acid positions of the heterozygous *NEK8* variants are marked by the red arrows. **e.** Structural modeling of the *NEK8* variants. **Inset a.** The predicted 3-dimensional structural model of human Serine/threonine-protein kinase *NEK8* generated using AlphaFold Protein Structure Database (<https://alphafold.ebi.ac.uk>) and UniProtKB (<https://www.uniprot.org/uniprot/>) with associated codes: AF-Q86SG6-F1 and Q86SG6 respectively. The protein contains a protein kinase domain (red) and five 'Regulator of Chromosome Condensation 1' (RCC1) repeat domains. **Inset b.** Missense SNV c.133C>T p.Arg45Trp modelled with the most probable (26.5% likelihood) rotamer demonstrated. **Inset c.** Missense SNV c.450C>G p.Ile150Met modelled with the most probable (28.5% likelihood) rotamer demonstrated. **Inset d.** Positions of both variants in b. and c. highlighted in yellow (and shown as 1. and 2., respectively) to demonstrate their juxtaposition in adjacent alpha-helices. The third variant c.469A>G p.Lys157Gln could not be predicted due to a low confidence score, but appears to be in close proximity to the other variants as highlighted by the arrow (shown as 3.). A known active site (4., proton acceptor) and autophosphorylation residue (shown as 5.) are also in close proximity to the variants.

## Figure 3. Analyses of the function of the NEK8 variants

(a) Sanger sequencing results of cDNA PCR products showed a nucleotide insertion in *Nek8* in the IMCD3 cell line, which causes a frameshift with early termination (45aa). (b-h) *Nek8* knockout cells (-/-) were transfected with the empty vector (Mock) or one of the Myc-tagged NEK8 constructs, including the wild type (WT) and indicated single-point mutations. Forty-eight-hr post transfection, cells were treated with G418 (1  $\mu$ g/mL) for one week. Cells survived the G418 selection were expanded, serum-starved for 24 h, and then subjected to the following analyses. Parental IMCD3 cells (+/+) were used as a positive control for endogenous *Nek8*, cells were harvested for immunoblotting (IB) with indicated antibodies, and  $\alpha$ -tubulin was used as a loading control (b, h). (b) IB with a Myc or NEK8 antibody showed that all NEK8 proteins were expressed. (c-g) Cells were subjected to immunofluorescence (IF) microscopy using the indicated antibodies to visualize Myc-tagged NEK8 variants (c), ARL13B (d), ANKS6 (e), GPR161 (f), or PC2 (g) (scale bar, 2  $\mu$ m). Primary cilia were labeled with an acetylated  $\alpha$ -tubulin (Ac-tub) antibody. Data were collected from >100 cilia in each experimental group. Results from three independent experiments were statistically analyzed and plotted as mean  $\pm$  SD. *P* values labeled in black were obtained by comparing to the group of *Nek8*<sup>-/-</sup>, mock transfected cells (-/-, Mock). *P* values labelled in red were obtained by comparing to the *Nek8*<sup>-/-</sup> cells stably expressing the wild type NEK8 (-/-, WT). (c) the NEK8 proteins with the various variants exhibited similar localization in cilia. (d, upper panel) Ciliogenesis was quantified by counting the percentage of ciliated (ARL13B and Ac-tub double-positive) cells and all cells were ciliated at a similar level; (d, lower panel) Loss of endogenous *Nek8* led to truncated cilia but all the NEK8 variants rescued the ciliary length defect except p.Lys157Gln (K157Q). The cilium length was measured by the length of ARL13B signal in cilia. (e) Loss of *Nek8* disrupted the recruitment of ANKS6 into cilia, which was fully rescued by all NEK8 variants, except p.Lys33Met (K33M) that only showed a partial rescue. (f) The percentage of GPR161-positive cilia were not affected by the expression status of NEK8. (g) The percentage of PC2-positive cilia and the fluorescence intensity of PC2 in cilia were both diminished by *Nek8* deficiency, although (h) IB showed that PC2 was present at comparable protein levels. (g) Different NEK8 variants exhibited different ability to rescue the ciliary trafficking of PC2. (i) Primary skin fibroblasts were isolated from healthy (WT) and p.Arg45Trp (Fam 1 and Fam 7, III-3) male donors. These cells were analysed by IF to visualize PC2 in cilia, with lower mean intensity seen for the two mutant cells. The percentage of PC2-positive cilia and the mean intensity of ciliary PC2 were quantified in >100 cilia from each group. Results from three independent experiments were statistically analysed and plotted as mean  $\pm$  SD. (j) HEK293T cells transfected with Myc-tagged wild type NEK8 (WT) or the p.Arg45Trp variant (R45W) were subjected to immunoprecipitation (IP) with anti-Myc antibody or normal mouse IgG (mIgG). The precipitates were then subjected to Phos-tag SDS-PAGE to separate the phosphorylated NEK8 (arrow) from the non-phosphorylated form and analysed by IB. The relative density of phosphorylated NEK8 was quantified from four independent experiments, statistically analysed, and plotted as mean  $\pm$  SD. (c-g, i, j) \*\*\*, *P* < 0.001; \*\*, *P* < 0.01; \*, *P* < 0.05; n.s., no statistically significant differences.

**Figure 4. Elevated DNA damage signaling in renal cell lines expressing NEK8 variants.** a. Representative images of  $\gamma$ H2AX signaling in IMCD3 cells with the

1 indicated genotypes. Scale bar is 50  $\mu\text{m}$ . Graph represents the mean of three  
2 independent experiments. Error bars represent sd. At least 150 nuclei per experiment  
3 were analyzed for  $>10$   $\gamma\text{H2AX}$  foci,  $**P < 0.01$ ,  $*P < 0.05$ . **b.** Representative images of  
4  $\gamma\text{H2AX}$  signaling in patient derived tubuloids with the indicated genotypes. Scale bar is  
5 50  $\mu\text{m}$  **c.** The percentage of  $\gamma\text{H2AX}$  positive cells from three independent experiments  
6 was quantified. Line represents the mean. Error bars are sd.  $**P < 0.01$ ,  $*P < 0.05$ .





**Table 1 – Clinical findings**

| Fam. - ind. | Inheritance    | NEK8 Variant | Allelic state | Gender | Year of birth | Age PKD diagnosis (years) | Suspected clinical diagnosis | Age at KFRT (years) | Age at KTx (years) | Enlarged kidneys | Liver cysts (age in years) | Hyper-tension | Other medical diagnoses                                                               |
|-------------|----------------|--------------|---------------|--------|---------------|---------------------------|------------------------------|---------------------|--------------------|------------------|----------------------------|---------------|---------------------------------------------------------------------------------------|
| 1           | <i>De novo</i> | Arg45Trp     | Het           | Male   | 2007          | 11                        | NPH vs. ADPKD                | 11                  | 12                 | +                | -                          | +             | -                                                                                     |
| 2           | <i>De novo</i> | Arg45Trp     | Het           | Female | 1986          | fetal                     | ARPKD                        | 4                   | 5                  | +                | -                          | +             | Alopecia                                                                              |
| 3           | <i>De novo</i> | Arg45Trp     | Het           | Male   | 2000          | 16                        | ADPKD/ARPKD                  | 19                  | 19                 | +                | -                          | +             | -                                                                                     |
| 4           | <i>De novo</i> | Arg45Trp     | Het           | Male   | 2011          | fetal                     | ADPKD                        | 5                   | 5                  | +                | -                          | +             | -                                                                                     |
| 5           | <i>De novo</i> | Arg45Trp     | Het           | Male   | 2000          | neonatal                  | ADPKD-VEO                    | 12                  | 13                 | +                | -                          | +             | Left ventricular hypertrophy                                                          |
| 6           | Unknown*       | Arg45Trp     | Het           | Female | 2002          | 9                         | ARPKD                        | 11                  | 12                 | -                | -                          | +             | unknown                                                                               |
| 7<br>II-8   | Mosaic         | Arg45Trp     | Mosaic (3%)   | Male   | ~1975         | unknown                   | ADPKD                        | 28                  | 32                 | unknown          | unknown                    | unknown       | unknown                                                                               |
| 7<br>III-3  | Familial       | Arg45Trp     | Het           | Male   | 2006          | 1.5                       | ADPKD                        | 14                  | 14                 | +                | -                          | +             | Kidney calcifications; short stature                                                  |
| 7<br>III-4  | Familial       | Arg45Trp     | Het           | Male   | 2006          | 1.5                       | ADPKD                        | 15                  | 15                 | +                | -                          | +             | Kidney calcifications; short stature                                                  |
| 8           | <i>De novo</i> | Arg45Trp     | Het           | Male   | N/A           | 2                         | ARPKD                        | 7                   | 7                  | +                | -                          | +             | Left ventricular hypertrophy and dilation; pericardial effusion; microhematuria       |
| 9<br>II-2   | Mosaic         | Arg45Trp     | Mosaic (6%)   | Female | N/A           | 3                         | ADPKD                        | 48                  | 48                 | +                | +                          | (48)          | Melanoma, basal cell carcinoma; migraines; aneurysm; liver hemangioma; diverticulitis |
| 9<br>III-1  | Familial       | Arg45Trp     | Het           | Female | N/A           | 0                         | ADPKD                        | 1                   | 3                  | +                | -                          | +             | Pre-eclampsia; B-cell m-PTLD; leukopenia; migraines; tertiary hyperparathyroidism     |
| 9<br>IV-1   | Familial       | Arg45Trp     | Het           | Female | N/A           | fetal                     | ADPKD                        | 6                   | 6                  | +                | -                          | +             | Gross hematuria; anemia; small for gestational age                                    |
| 10          | Unknown*       | Arg45Trp     | Het           | Female | 2004          | 3                         | NPHP (MSK)                   | N/A                 | N/A                | +/-              | -                          | in the past   | -                                                                                     |
| 11<br>II-1  | Familial       | Ile150Met    | Het           | Female | 1924          | >70                       | ADPKD                        | 70s                 | N/A                | -                | -                          | +             | Retinal dystrophy with <i>PRPH2</i> variant                                           |
| 11<br>III-1 | Familial       | Ile150Met    | Het           | Female | 1954          | 43                        | ADPKD                        | N/A                 | N/A                | -                | +                          | (52)          | Retinal dystrophy with <i>PRPH2</i> variant                                           |
| 11<br>III-2 | Familial       | Ile150Met    | Het           | Male   | 1956          | 40                        | ADPKD                        | N/A                 | N/A                | +/-              | -                          | +             | Retinal dystrophy with <i>PRPH2</i> variant                                           |
| 11<br>III-3 | Familial       | Ile150Met    | Het           | Female | 1961          | 40                        | ADPKD                        | N/A                 | N/A                | -                | -                          | -             | -                                                                                     |
| 11<br>IV-3  | Familial       | Ile150Met    | Het           | Male   | 1994          | 14                        | FSGS vs. ADTKD               | N/A                 | N/A                | -                | -                          | -             | Asthma                                                                                |
| 11<br>IV-4  | Familial       | Ile150Met    | Het           | Female | 1995          | 18                        | FSGS                         | N/A                 | N/A                | -                | +                          | (18)          | Asthma                                                                                |
| 12          | <i>De novo</i> | Lys157Gln    | Het           | Male   | 2017          | Fetal                     | ARPKD                        | 4                   | 4                  | +                | -                          | +             | Severe feeding difficulties (PEG-J)                                                   |

ADPKD = autosomal dominant polycystic kidney disease; ARPKD = autosomal recessive polycystic kidney disease; ADTKD = autosomal dominant tubulointerstitial kidney disease; FSGS = focal segmental glomerulosclerosis; MSK = medullary sponge kidney; KFRT = kidney failure with replacement therapy; KTx = kidney transplantation; NPH = nephronophthisis; m-PTLD = monomorphic post-transplant lymphoproliferative disorder; VEO = very early onset | Roman numerals indicate generation | \* DNA from father not available for segregation; mother, and in family 6 also sibling, negative for *NEK8* variant | in family 11 three family members had retinal dystrophy which segregated with a likely pathogenic variant in *PRPH2*, individual III-3 tested negative for the *PRPH2* variant and had a normal retinal exam.

Journal Pre-proof



Journal Pre-proof

